The effect of bone marrow-derived mesenchymal stem cell co-transplantation with hematopoietic stem cells on liver fibrosis alleviation and survival in patients with class III β-thalassemia major.
Tahereh RostamiAmir KasaeianNasrollah MalekiMohsen NikbakhtAzadeh KiumarsiSeyed Mohammad TavangarAmir Pejman Hashemi TaheriSeied Asadollah MousaviArdeshir GhavamzadehPublished in: Stem cell research & therapy (2021)
Based on the results of this study, a single infusion of MSCs at the time of HSCT to patients with class III beta-thalassemia major could not significantly improve the liver fibrosis alleviation and transplantation outcomes, including OS, TFS, TRM, rejection rate, ANC engraftment, platelet engraftment, acute GvHD, and chronic GvHD.
Keyphrases
- liver fibrosis
- mesenchymal stem cells
- hematopoietic stem cell
- cell therapy
- induced apoptosis
- umbilical cord
- allogeneic hematopoietic stem cell transplantation
- liver failure
- sickle cell disease
- drug induced
- bone marrow
- low dose
- metabolic syndrome
- stem cells
- acute lymphoblastic leukemia
- signaling pathway
- aortic dissection
- free survival
- skeletal muscle